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EXPERIMENTAL STUDIES
Angiogenesis Is Enhanced in Ischemic Canine Myocardium by
Transmyocardial Laser Revascularization
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CAROLYN DEROSA, BS, CRAIG R. SMITH, MD, DANIEL BURKHOFF, MD, PHD
New York, New York
Objectives. This study sought to test whether transmyocardial
laser revascularization (TMLR) stimulates angiogenesis in an
animal model of chronic ischemia.
Background. TMLR relieves angina and may also improve
blood flow in patients who are not candidates for traditional
therapies. The mechanisms of these benefits are not fully defined.
Methods. Ischemia was created in 14 dogs by proximal left
anterior descending coronary ameroid constrictors. TMLR was
performed in the anterior wall (;1 channel/cm2) of seven dogs;
the remaining dogs served as the ischemic control group. Myo-
cardial blood flow was measured (colored microspheres) at rest
and during chemical stress (adenosine) in the acute setting and
after 2 months.
Results. TMLR did not influence blood flow in the acute setting.
After 2 months, resting blood flow increased comparably in the
anterior wall in both groups to ;80% of normal. However, the
TMLR-treated dogs demonstrated an ;40% increase in blood flow
capacity during stress in the ischemic territory compared with
untreated dogs (left anterior descending coronary artery/left
circumflex coronary artery flow 0.53 6 0.16 in the control group
vs. 0.73 6 0.08 in TMLR animals, p < 0.05). Vascular prolifera-
tion, assessed by bromodeoxyuridine incorporation and prolifer-
ating cell nuclear antigen positivity in endothelial and smooth
muscle cells was about four times greater in the TMLR group than
in the control group (p < 0.001). The density of vessels with at
least one smooth muscle cell layer was ;1.4 times greater in the
myocardium surrounding the TMLR channel remnants than in
control ischemic tissue (p < 0.001).
Conclusions. In this canine model of chronic ischemia, TMLR
significantly enhances angiogenesis as evidenced by the increased
number of vessels lined with smooth muscle cells, markedly
increased vascular proliferation and increased blood flow capacity
during stress.
(J Am Coll Cardiol 1998;31:1426–33)
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Significant advances have been made in the development of
new surgical and percutaneous techniques to restore blood
flow through diseased coronary arteries. However, most of
these advanced therapies are primarily designed to treat
relatively discrete vascular stenoses. It has become increasingly
evident that there are a growing number of patients who suffer
from debilitating angina who cannot be treated by these
therapies, typically because the extent of the vascular disease is
too diffuse. Accordingly, there is interest in developing alter-
native forms of therapy to relieve angina and improve blood
flow to ischemic myocardium.
Transmyocardial laser revascularization (TMLR), one such
therapy currently under active clinical investigation, has re-
ceived a great deal of attention because results of several
studies indicate that it provides significant relief of angina and
may improve myocardial perfusion in otherwise untreatable
patients (1–4).
During TMLR surgery, a laser is used to create channels
through the myocardial wall that penetrate into the ventricular
chamber. The original idea behind TMLR was to mimic the
naturally occurring channels of reptile hearts, which permit a
substantial amount of myocardial perfusion directly from the
ventricular chamber (1,5), thus diminishing the reliance of
myocardial perfusion on the epicardial arteries. However,
results of recent experimental studies have indicated that laser
channels made in mammalian hearts do not conduct blood
(6,7). Furthermore, the channels do not remain patent, but are
rapidly occluded by thrombus and infiltrated by granulation
tissue within 3 weeks (6–11). (We use the term patent chronic
channel to specifically denote a chronic channel whose inner
dimensions approximate those of the channels at the time
when they are created.) Accordingly, investigators have begun
to consider other possible mechanisms by which clinical ben-
efits could be achieved, with significant interest focused on the
possibility that the TMLR stimulates angiogenesis. A recent
study from our laboratory documented a doubling of arteriolar
density in the normal myocardium immediately surrounding
the TMLR channel remnants, with evidence of active vascular
growth 3 weeks after the procedure (12). However, the degree
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to which TMLR stimulates this angiogenic process under
clinically relevant ischemic conditions, whether the new vessels
persist for longer periods and whether the new vessels are
capable of mediating an increase in local blood flow are all
unexplored, fundamental questions.
To gain further insight into the potential mechanisms
underlying the clinical benefits of TMLR, these questions were
investigated in a chronic canine model of ischemia. An amer-
oid constrictor was placed on the proximal left anterior de-
scending coronary artery (LAD) and TMLR channels were
created in the anterior wall; a separate group of control dogs
underwent ameroid placement without the TMLR procedure.
Blood flow was measured with microspheres at rest and during
adenosine-induced stress at the initial operation and 2 months
later. Evidence of vascular growth was obtained through vessel
counting and by detecting proliferation of vascular endothelial
and smooth muscle cells in the tissue retrieved at the 2-month
evaluation. Although there was no acute effect of TMLR on
blood flow, this procedure significantly stimulated vascular
growth in the chronically ischemic myocardium; this was
associated with increased blood flow capacity during stress, a
finding that mimics those obtained in the clinical setting (2,3).
These studies provides evidence that angiogenesis may be a
mechanism by which blood flow is improved by TMLR, which
is emerging as a therapy for patients with severe coronary
artery disease.
Methods
All dogs were cared for by a veterinarian in accordance with
the “Principles of Laboratory Animal Care” formulated by the
National Society for Medical Research and the “Guide for the
Care and Use of Laboratory Animals” prepared by the Na-
tional Academy of Sciences (National Institutes of Health
publication 85-23, revised 1985) and the “Position of the
American Heart Association on Research Animal Use” (No-
vember 11, 1984).
Surgical procedures. Fourteen adult mongrel dogs of ei-
ther gender, weighing 21 to 26 kg, were anesthetized with an
intravenous injection of thiopental sodium (15 mg/kg body
weight). The anesthesia was maintained with 0.5 to 2.0%
inhaled isoflurane. The femoral artery was cannulated to
monitor arterial blood pressure and to take samples of arterial
blood. A left thoracotomy was performed through the fifth
intercostal space using a sterile technique. Two catheters were
introduced into the left atrial appendage through a pursestring
suture (4–0 polypropylene); one catheter was for injection of
microspheres and the other for the infusion of adenosine. In
the TMLR group (n 5 7) transmural laser channels were
created from the epicardial surface into the ventricular cham-
ber over the LAD territory (anterior and anteroapical region
of the heart). A fiberoptic cable with a 1.75-mm focusing lens
(CardioGenesis Co.) connected to a holmium:yttrium-
aluminum-garnet laser (CardioGenesis Corp.) was used to
create the channels. The firing of the laser was synchronized
with the R wave of the electrocardiogram to deliver a burst of
three pulses (2 J/pulse) in rapid succession; three to five bursts
(between 18 and 30 J total energy) were required to create
each transmural channel. Channels were made with a density
of ;1 channel/cm2, and an average of 14 channels (range 11 to
19) were made in each heart.
All visible epicardial collaterals connecting LAD diagonals
to the left circumflex coronary artery (LCx) or right coronary
artery were ligated with a 4–0 stitch to minimize collateral flow
to the LAD territory; an average of four such collateral vessels
were identified in each heart. In order to assess the blood flow
capacity of the remaining collateral circulation, 1 ml of mixed
colored microsphere solution (15 mm diameter, 3z106 micro-
spheres/ml in a saline suspension with 0.01% Tween 80 and
thimerosal, Dye-Trak, Triton Technology, Inc.) was injected
into the left atrium through the previously inserted catheter
while temporarily clamping the LAD proximal to the first
diagonal branch. To assess collateral flow during stress, micro-
spheres of a different color were injected after left atrial
adenosine infusion. The rate of infusion was titrated as in
previous studies (13) to create an ;20% fall in mean arterial
pressure (MAP); as with the baseline measurement, this
infusion was performed while temporarily clamping the LAD.
Blood samples were obtained during microsphere injections by
a constant rate of withdrawal (7 ml/min) from the femoral
artery using a syringe pump. After microsphere injections
under both baseline and stress conditions, an ameroid constric-
tor was placed on the LAD at the same location (i.e., proximal
to the first diagonal branch). The control group (n 5 7)
underwent the same procedures described earlier, except that
no TMLR channels were made. After completion of the
procedure, the chest was closed in layers and the dog was
allowed to recover from anesthesia.
In order to provide an index of cellular proliferation at
multiple time points after the initial surgery, bromodeoxyuri-
dine (BrdU, 25 mg/kg, Sigma) was administered subcutane-
ously in four TMLR and four control animals on postoperative
days 7, 14 and 28.
The final procedure was performed 8 to 9 weeks after the
initial operation. The dogs were anesthetized and mechanically
ventilated and a median sternotomy was performed. The same
protocol of microsphere infusions under rest and adenosine
stress conditions described earlier was performed using micro-
spheres of two additional colors; the only difference was that
the LAD was not clamped because, as expected from previous
reports and as shown by direct evaluation after euthanasia,
Abbreviations and Acronyms
BrdU 5 bromodeoxyuridine
LAD 5 left anterior descending coronary artery
LCx 5 left circumflex coronary artery
MAP 5 mean arterial pressure
PCNA 5 proliferating cell nuclear antigen
SMA 5 smooth muscle actin
TMLR 5 transmyocardial laser revascularization
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every ameroid constrictor was completely occluded. After
euthanasia (pentobarbital 100 mg/kg), the heart was removed
and cut into small (;1 g) transmural samples from the
LAD-laser channel region (one channel per sample) and from
the LCx region. Three LAD and two LCx myocardial samples
were submitted for immunohistochemical analysis; all other
samples were submitted for microsphere analysis.
Microsphere analysis. Retrieval and quantitative analysis
of the microspheres were performed exactly as described
previously (6,14). In brief, tissue samples were digested and the
microspheres were retrieved by filtration of the digestate. The
dye on the microspheres was then itself digested into solution
using dimethylformamide and the photometric absorption of
the resulting sample was measured by a diode array spectro-
photometer (model 8452A, Hewlett-Packard Co.). The com-
posite spectrum was then resolved at the peak frequencies into
the contributions from the individual colored microspheres
using a matrix inversion technique (6,14). The number of
microspheres in each sample was calculated according to the
optical density at the wavelength corresponding to each dye
color using standardization curves generated from known
quantities of microspheres from the same batch of spheres.
Regional myocardial blood flow (RMBF, ml/min per g) was
calculated using the following equation:
RMBF 5
Fref
Msample
3
ODsample
ODref
, [1]
where Fref represents the rate at which arterial blood is
withdrawn from the femoral artery (i.e., of the reference
sample, which was always 7 ml/min in our study); ODref
represents the optical density of the dye solution obtained
from this reference sample; Msample represents the mass of the
respective myocardial sample; and ODsample represents the
optical density at the corresponding wavelength of the dye
solution obtained from the myocardial sample.
Tissue fixation and preparation. Myocardial samples des-
tined for histologic evaluation were fixed in 10% neutral
buffered formalin, left overnight and routinely dehydrated and
embedded in paraffin. Serial sections, 4 to 5 mm thick, were cut
and stained with Masson’s trichrome stain to evaluate the
general morphology of the lased and nonlased myocardium.
Sister sections were stained using standard immunohistochem-
ical techniques with antibodies against BrdU (15), PC10
proliferating cell nuclear antigen (PCNA) (16), and alpha
smooth muscle actin (SMA) (17), using standard techniques.
Statistical analysis. All data are presented as mean
value 6 SD. The statistical significance of differences between
groups was determined by the Student t test or analysis of
variance with a Tukey post hoc test in cases when multiple
groups were being compared. A p value , 0.05 was considered
significant.
Results
Coronary blood flow in acute and chronic settings. Coro-
nary blood flow to the LCx territory averaged 0.9 6
0.24 ml/min per g in the control group and 1.30 6 0.63 ml/min
per g in the TMLR group (p 5 NS). With all visible epicardial
collateral vessels between the LCx and LAD territory perma-
nently ligated, and with the LAD itself temporarily clamped
during the measurements, residual collateral flow into the
LAD territory averaged ;25% of the flow in the LCx territory
in both groups (Fig. 1). Adenosine infusion decreased MAP
from 81 6 11 to 69 6 11 mm Hg (21% decrease) in the control
group and from 85 6 13 to 65 6 11 mm Hg (24% decrease) in
the TMLR group (p 5 NS). Despite the drop in MAP,
coronary flow into the LCx territory increased to 1.89 6
1.51 ml/min per g in the control group and to 2.02 6
1.20 ml/min per g in the TMLR group (p 5 NS), indicating
significant coronary vasodilation. However, because of the
relatively limited reserve of the preexisting collateral vessels,
flow into the LAD territory was only ;12% that of the LCx
territory (Fig. 1); there was no difference in this response
between the two groups. Thus, TMLR did not affect regional
myocardial blood flow in the acute setting, neither at baseline
conditions nor during the stress of a pharmacologically in-
duced vasodilator challenge.
After 2 months, the dogs were again anesthetized and the
chest was opened and coronary blood flow measured at
baseline and during the same pharmacologically induced stress
using microspheres. Blood flow to the LCx territory at rest was
unchanged from the acute setting, averaging 0.98 6
0.36 ml/min per g in the control group and 1.14 6 0.49 ml/min
Figure 1. Color microsphere measurement of blood flow into ischemic
anterior wall (LAD distribution) showed that flow was normal com-
pared with flow in the normally perfused circumflex territory in control
(n 5 7) and TMLR-treated (n 5 7) hearts. In the acute setting, TMLR
had no influence on flow in the ischemic territory. During adenosine-
induced vasodilatory stress, relative flow decreased further in the
anterior wall, but again TMLR did not influence flow. In the chronic
(2-month) setting, blood flow at rest increased comparably in both
control and TMLR-treated groups, reflecting the normal process of
angiogenesis that occurs in response to ischemia. However, during
vasodilatory stress, blood flow was better maintained in the TMLR
group, suggesting that angiogenesis was enhanced by TMLR. Normal-
ized flow was significantly less during adenosine-induced stress than
under corresponding flow at rest in all cases, except in the TMLR
group in the chronic study where these two values did not differ. Also,
analysis showed that in the chronic study during adenosine stress,
relative flow was greater in the TMLR group than in the control group.
Bars indicate pairs that were statistically different from each other
based upon analysis of variance with the Student-Newmann-Keuls
post-hoc test; p , 0.05 considered significant. See text for details.
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per g in the TMLR group (p 5 NS). Flow to the LAD territory
at baseline increased comparably in both groups: to 77 6 16%
of LCx flow in the control hearts and to 90 6 15% in the
TMLR hearts (p 5 NS, Fig. 1). Thus, although not returning to
normal, there was a marked increase in collateral flow into the
chronically ischemic bed; under these conditions there was no
apparent effect of TMLR, although there was a trend for flow
to be increased.
However, during adenosine-induced stress there was a
statistically and physiologically significant difference in blood
flow response in the LAD territory (Fig. 1). Adenosine infu-
sion decreased MAP from 95 6 12 to 76 6 12 mm Hg (20%
decrease) in the control group and from 102 6 20 to 77 6
19 mm Hg (25% decrease) in the TMLR group. Collateral flow
into the LAD territory was only ;53% that of the LCx
territory; this value was ;73% in the TMLR-treated dogs (p ,
0.05). Statistical analysis showed that relative LAD flow was
decreased during adenosine infusion in the control group, but
there was no statistically significant difference between base-
line and stress in the TMLR group. Importantly, the relative
blood flow during adenosine-induced stress was significantly
increased in the TMLR group compared with the control
group. Thus, TMLR was associated with an almost 40%
increase in blood flow reserve in the chronically ischemic
myocardium (i.e., a 20-percentage point increase over the
control value of 53%).
Histologic and immunohistochemical findings. The histo-
logic appearance of myocardium 2 months after being treated
with TMLR (Fig. 2) was similar to what has been reported at
2 weeks (6,7,18), except that there was no significant active
inflammation. The channels, which were approximately 1 mm
in diameter in the acute setting, were infiltrated with granula-
tion tissue that included a significant amount of vascularity.
Because the channels are not “patent” in the sense of retaining
an internal bore with diameter comparable to that at the time
of its creation, we have called these regions channel remnants.
The regions of granulation were generally longer in the fiber
direction, averaging 3.3 6 0.7 mm in length and 1.3 6 0.3 mm
in width. The typical appearance of channel remnants is shown
in the transverse and longitudinal sections of Figure 2A and
2D, respectively. Relatively large, mature arterial vessels fre-
quently existed within the core of these channel remnants.
SMA immunostaining of these tissue clearly revealed the
vessels within the remnants (Fig. 2B and 2E). Simply on the
basis of their high density within the channel remnant, it is
evident that these are new vessels and thus represent the result
of a significant angiogenic process. The typical examples shown
in Figure 2C and 2F reveal that many smooth muscle and
endothelial cells of these vessels incorporated BrdU. These
findings confirm that these vessels had been actively growing
during the times of BrdU administration (and also served as a
positive control for the assay). For comparison, examples
obtained from the remote, nonischemic LCx territory of these
hearts show very little BrdU incorporation and, when present,
was observed mostly in small vessels and capillaries (Fig. 3B).
PCNA positive nuclear staining was rare in this and in all other
tissue examined (assay validated using canine intestinal mu-
cosa as a positive control); this indicates that the phase of
active vascular growth revealed by the BrdU staining was
completed by 2 months after the TMLR procedure.
Vascular density appeared increased in the normal myocar-
dium surrounding the channel remnants compared with the
vascular density in the nonischemic LCx territory (Fig. 4, edge
of channel remnant in the upper left corner of panel A).
Significant amounts of nuclear BrdU incorporation, and there-
fore antecedent vascular growth, were noted in small (Fig. 4B
and 4C), intermediate (Fig. 4D and 4E) and large (Fig. 4F)
vessels outside of the channel remnants. As for the other
regions examined, PCNA staining was rarely observed in these
vessels, indicating low levels of active proliferation.
BrdU incorporation was also detected in the ischemic tissue
of control hearts. An example of a new collateral vessel that
formed a bridge between two preexistent arteries is shown in
the low magnification, trichrome-stained tissue of Figure 5A.
Immunostaining (Fig. 5B and 5C) revealed that many of the
endothelial cells along the entire length of this vessel stained
positive for BrdU incorporation, a finding that confirms that
Figure 2. Histologic appearance of channel remnants 2 months after
creation. A, to C, Sections of a transverse cut through a channel
remnant. D to F, Sections of the endocardial side of a longitudinally
cut sample. Trichrome stains (A and D, original magnification 320)
show the region to be infiltrated with granulation tissue without active
inflammation at this time. Smooth muscle actin immunostaining (B
and E, original magnification 340) highlights vessels within the
granulation tissue. Examples of BrdU incorporation (dark staining
nuclei into smooth muscle and endothelial cells of vessels within
channel remnants (C and F, original magnification 3400) indicate that
these vessels had undergone significant growth after the TMLR
procedure. Calibration bar shows 1 mm for panels A and D; 0.5 mm for
B and E; 0.05 mm for C and F.
1429JACC Vol. 31, No. 6 YAMAMOTO ET AL.
May 1998:1426–33 TMLR ENHANCES ANGIOGENESIS
this is a new vessel. As with the other examples, there was no
PCNA staining observed in the cells of this vessel. Also as in
this typical example, BrdU incorporation was rarely seen in the
smooth muscle or endothelial cells of large arteries (Fig. 5D).
Tissue samples obtained from the remote, nonischemic
tissue of the LCx territory of each heart were also examined.
As shown in Figure 3, examination of low magnification views
of SMA-stained samples revealed a relatively low density of
arterial structures with one or more layers of smooth muscle in
both control (Fig. 3C) and TMLR-treated (panel A) hearts;
note that in creating these photographs, regions were specifi-
cally chosen so as to provide the maximal number of vessels in
the field as possible. Furthermore, as reviewed earlier, BrdU
positive staining was very rare in smooth muscle or endothelial
cells of the vessels in the normal region; as shown in Figure 3B
and 3D, when found it was typically present in only a single cell
per vessel cross-section.
In order to provide a quantitative assessment of the various
observations, we determined vascular density (number of
vessels with at least one layer of smooth muscle cell/cm2) and
proliferating cell density (positive BrdU and positive PCNA
vascular smooth muscle or endothelial cells/cm2) in several
areas of each heart. The results of this analysis are summarized
in Figure 6. In control hearts, vascular density (Fig. 6C) was
comparable in the LCx and anterior regions; this was also
similar to the vascular density in the LCx region of the TMLR
hearts. The vascular density in the myocardium immediately
surrounding the channel remnants (contained between the
edge of the channel remnant and an ellipse with a minor axis
of 6 mm and a major axis of 10 mm) was approximately twice
that of the LCx territory. Furthermore, in the region neighbor-
ing the channel remnant (with boundaries defined by the first
ellipse and a second, concentric ellipse with a minor axis of
10 mm and a major axis of 14 mm), vascular density was still
significantly increased compared with the LCx territory. The
Figure 3. Samples from the nonischemic LCx territory obtained from
TMLR-treated (A and B) and control hearts (C and D). SMA-stained
samples (A and C) show the normal density of vessels in both groups
of hearts (original magnification 340). Sparse BrdU incorporation
(arrows in panels B and D) indicates that, as expected in normally
perfused myocardium, there was very little vascular proliferation in
these areas. Calibration bar shows 1 mm for panels A and C; 0.1 mm
for panels B and D.
Figure 4. SMA stain (A; original magnification
340) shows generally increased vascular density
compared with normal and ischemic myocardium
in the region surrounding the TMLR channel
remnant (edge of channel remnant toward upper
left corner of panel). Examples of BrdU incorpo-
ration into vessels in normal myocardium near the
remnants in small (B, magnification 3100 and C,
3400) intermediate (D and E, 3400) and large (F,
3400) vessels indicate previous growth of these
vessels and provide evidence for an angiogenic
process. Calibration bar shows 1 mm in panel A;
0.25 mm in B; 0.1 mm in C through F.
Figure 5. Trichrome-stained tissue in ischemic territory of a control
(non-TMLR) heart shows a small, thin vessel (arrows) bridging two
larger vessels. Examples of nuclear BrdU incorporation (B and C,
original magnification 3400) into endothelial cells along the entire
course of this vessel confirmed that this was a new, bridging collateral.
By contrast, BrdU incorporation into larger arteries of these hearts
was rarely observed, even in the ischemic territory (D, original
magnification 3100). Calibration bar shows 1 mm for panel A;
0.05 mm for B and C; 0.20 mm for D.
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number of PCNA positive staining nuclei (Fig. 6B) was very
low in all regions, although it was increased in the area
immediately surrounding the channel remnant. Similarly, com-
pared with all other regions in both groups of hearts, BrdU
incorporation (Fig. 6A) was increased in the region immedi-
ately around the channel.
Discussion
Evidence has been accumulating that angiogenesis may be
an important factor contributing to the clinical benefits ob-
served after TMLR. Previously, this evidence has been derived
from observations made in experimental tissue and in autopsy
specimens that many, apparently new, blood vessels appear
within the granulation tissue that invades the original channels
(i.e., neovascularization within the channel remnants) (6–
10,18–20). Such observations, however, provide limited sup-
port for the angiogenesis hypothesis because blood vessels
within scar tissue by themselves may not contribute meaning-
fully to myocardial perfusion. More recently, we showed that
by 2 weeks after creating transmyocardial laser channels in
normal canine hearts active vascular growth in the normal
myocardium surrounding TMLR channel remnants occurs
(12), with vascular density increasing to approximately twice
that of normal. Although these findings indicated that vessels
are growing in the myocardium surrounding the treated region,
questions remained as to whether this increased vascularity
persists over longer periods, whether and to what degree such
vessels could mediate an increase in blood flow and how
myocardial ischemia might impact on this process.
Canine model of chronic ischemia. The present study was
performed in a canine model of chronic ischemia created with
the use of an ameroid constrictor (which gradually closes
within 2 to 3 weeks) in combination with surgical ligation of all
visible epicardial collateral vessels that connect to the LAD
circulation. Microsphere assessment of regional blood flow in
the control group confirmed that we were successful in creating
significant anterior wall ischemia. As has been observed pre-
viously, collateral blood flow in the acute setting was ;25% of
normal under conditions at rest, but only ;12% of normal
during adenosine-induced vasodilation. In the chronic setting,
however, blood flow at rest increased to ;80% of normal,
demonstrating the natural increase in collateral flow over time
due to the angiogenesis that was stimulated by chronic isch-
emic conditions (21,22); this same degree of recovery of blood
flow at rest has been observed by other investigators in both
porcine and canine models of chronic ischemia. Concordant
with this increase in blood flow at rest, evidence of endothelial
and, to a lesser extent, smooth muscle proliferation (BrdU
incorporation) confirmed vascular growth, including growth in
capillaries and bridging collateral vessels. Nevertheless, limita-
tions of the blood flow capacity of this collateral network were
exposed when the vasculature was challenged by a vasodilator,
at which point blood flow into the collateral-dependent bed
decreased to ;50% that of the control region.
Effects of TMLR. TMLR significantly influenced vascular
growth patterns and collateral blood flow potential in the
chronic setting. Compared with the ischemic region of the
control hearts, there was a significant increase in the number of
vessels in the region ;3 mm beyond the edge of the TMLR
channel remnants. Although we observed the growth of capil-
laries and new small arteries similar to those observed in the
ischemic areas of the control hearts, significant growth was also
observed in larger arteries. The finding that many of the
smooth muscle and endothelial cells of these vessels exhibited
BrdU incorporation provide corroborating evidence that these
vessels had been stimulated to grow after the TMLR proce-
dure. Evidence of the functionality of these vessels was ob-
tained from the microsphere blood flow analysis, which re-
vealed an almost 40% increased blood flow capacity during
vasodilatory stress. These findings suggest that TMLR signifi-
cantly enhances the normal compensatory development of
collateral vessel development. Histologic findings corrobo-
rated that TMLR enhances the normal angiogenic process,
because significant growth of large vessels in the myocardium
surrounding the channel remnants was routinely observed
following TMLR and rarely observed in the ischemic myocar-
dium of the control hearts.
Our previous studies have shown that blood does not flow
through TMLR channels, neither in the acute setting nor 2
weeks after the procedure (6,7). Consistent with our previous
studies, the current results obtained in the acute setting
showed that the presence of TMLR channels did not affect
blood flow. Thus, improved blood flow was not immediate, but
Figure 6. Quantitative analysis of BrdU, PCNA and vessel density in
control and TMLR-treated hearts. LCx, data from nonischemic,
normally perfused left circumflex territory; LAD, data from ischemic
anterior wall of control hearts; LADI, data from anterior wall myocar-
dium immediately surrounding channel remnants (i.e., confined be-
tween edge of remnant and an ellipse with minor and major axes of 0.6
and 1.0 cm, respectively); LADN, data from anterior wall myocardium
neighboring the channel remnants (i.e., confined between the first
ellipse and a second concentric ellipse with axes of 1.0 and 1.4 cm).
Each bar graph represents mean value 6 SD of observations made
from 21 observations (3 from each heart studied). *p , 0.05 by analysis
of variance with the Student-Newmann-Keuls post hoc test.
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rather was gradual. Although not specifically studied in the
chronic setting, the relatively rare observation of vessels ex-
tending from the channel remnant to the endocardial surface
renders it unlikely that the source of the increased blood flow
is derived from the ventricular chamber. Rather, increases in
blood flow of the magnitude observed in the present study
would more likely be mediated by collateral vessels communi-
cating with the surrounding normal myocardium. Nevertheless,
direct blood flow from the chamber has not been totally
excluded and may be a contributing factor.
Underlying mechanisms. The factors responsible for stim-
ulating angiogenesis after TMLR have not been elucidated.
Myocardial injury created by the laser application results in an
inflammatory response that is evident within days of the
procedure and persists for about 4 weeks (9,10,18). Recent
studies have revealed that several growth factors and cytokines
commonly liberated by inflammatory cells promote angiogen-
esis (e.g., vascular endothelial growth factor [VEGF] and basic
fibroblast growth factor [bFGF]) and up-regulates receptors
for these factors. The general features of such a response are
likely to not be unique to laser injury but would be expected
with any type of injury affecting a similar amount of myocar-
dium. These features stimulate budding and growth of small
vessels from preexistent blood vessels (“true angiogenesis”
[21]) and remodeling of preexistent vessels by endothelial and
smooth muscle cell proliferation, leading to an increased
luminal diameter. Another mechanism that may be involved is
vasculogenesis, the formation of new blood vessels, which, until
recently, was believed to be confined to the period of embry-
ogenesis (21,23). However, stem cells capable of differentiating
into endothelial cells have been shown to be circulating in the
blood of adults and these migrate to ischemic tissue where they
may assemble and form new vessels (23). Elucidation of the
mechanisms underlying TMLR as they may relate to the role
of myocardial injury, the subsequent inflammatory response
and the induction of growth factors, may help devise schemes
to optimize or even enhance the therapy.
Study limitations. Several potential limitations of the
present study should be recognized. First, it is well known that
the ameroid constrictor model of ischemia is not a faithful
model of human ischemic heart disease in several respects.
Therefore, the results may not be directly applicable to the
clinical situation. Although perhaps not ideal, it must be
recognized that despite these and other limitations, a great
deal of useful information about myocardial angiogenesis has
been obtained in this type of animals model (13,21,22). Sec-
ond, we relied on the comparability of the acute flow data to
indirectly substantiate that the degree of ischemia was truly
comparable between the two groups of dogs. An alternative
approach would have been to create a chronic ischemic model
and then to randomize animals between the TMLR and
control groups. That experimental paradigm would more
closely mimic the clinical situation in which TMLR is applied.
Conclusions. With growing recognition that there are a
large number of patients with one or more diffusely athero-
sclerotic epicardial coronary arteries in whom methods of
direct coronary revascularization cannot be applied, there has
been renewed interest in investigating alternate techniques to
improve myocardial perfusion, such as TMLR. Reports of
substantial and persistent reduction of angina in otherwise
untreatable patients (2,3) and preliminary studies showing that
over time, blood flow may increase in TMLR-treated myocar-
dium (2,3) have stimulated a great deal of basic and clinical
studies. The original idea behind the development of TMLR
was to mimic the physiology of myocardial perfusion in rep-
tiles, which derive a significant blood supply from an extensive
network of large, branching channels emanating directly from
the ventricular chamber. As revealed in a recent detailed study
of alligator hearts (24), perfusion of a substantial amount of
myocardium is possible because of the large surface area and
short diffusion distance for nutrient and waste exchange cre-
ated by this channel network. With increased recognition that
TMLR channels do not conduct significant amounts of blood
(6,7,25), that the amount of myocardium in close proximity to
the channels is limited and that TMLR channels do not remain
patent (6–11,18,19,26), it has become evident that TMLR does
not mimic reptilian physiology and this hypothesis is falling out
of favor (24,27). In its place, the angiogenesis hypothesis is
gaining wider acceptance. Results of clinical studies showing
that myocardial perfusion of treated regions increases over
time also suggests involvement of a mechanism such as angio-
genesis. Although several questions remain, the results of the
present study provide the strongest, most comprehensive sup-
port to date that angiogenesis is enhanced by the TMLR
procedure to an extent that may augment collateral blood flow
into ischemic myocardium. This study represents a further step
in the arduous task of unraveling how TMLR may provide
clinical benefits. The findings of significant amounts of smooth
muscle proliferation and an increased number of vessels with
one or more layers of smooth muscle cells, neither of which
were observed with any regularity in the control ischemic
tissue, reveals a novel pattern of vascular growth induced by
this form of therapy.
We are grateful to Pedram Faily and Steve Winikoff for expert surgical
assistance.
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